# Pyxis Oncology, Inc.: overview

PYXS · Nasdaq · CIK 1782223 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pyxs.md) · [Financials](/companies/pyxs/financials.md) · [Filings](/companies/pyxs/filings.md) · [Insiders](/companies/pyxs/insiders.md)

Latest reported revenue: [$11.0m](/filings/0001193125-26-118532.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 23, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-118532).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0 d](/filings/0001193125-25-261696.md) | [0.0 d](/filings/0001193125-26-118532.md) | not reported | [2.8](/filings/0000950170-25-108906.md) | [0.0 d](/filings/0001193125-25-261696.md) | [11.0 d](/filings/0001193125-26-118532.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | [(700.4%)](/filings/0001193125-26-347913.md) | not reported | [(165.7%) d](/filings/0001193125-26-118532.md) | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | [(650.9%)](/filings/0001193125-26-347913.md) | not reported | [(164.0%) d](/filings/0001193125-26-118532.md) | not reported | not reported |
| Diluted EPS | $ per share | [(0.35)](/filings/0001193125-25-261696.md) | not reported | [(0.35)](/filings/0001193125-26-222843.md) | [(0.30)](/filings/0001193125-26-347913.md) | [(0.35)](/filings/0001193125-25-261696.md) | not reported | [(0.37)](/filings/0001193125-26-222843.md) | [(0.40)](/filings/0001193125-26-347913.md) |
| Free cash flow | $m | [(14.7) d](/filings/0001193125-25-261696.md) | [(19.3) d](/filings/0001193125-26-118532.md) | not reported | not reported | not reported | [(10.4) d](/filings/0001193125-26-118532.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [16.1](/filings/0001193125-26-118532.md) | [13.9](/filings/0001193125-26-118532.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | [(554.1%)](/filings/0001193125-26-118532.md) | [(609.2%)](/filings/0001193125-26-118532.md) |
| Net margin | % | not reported | not reported | not reported | [(478.9%)](/filings/0001193125-26-118532.md) | [(574.5%)](/filings/0001193125-26-118532.md) |
| Diluted EPS | $ per share | [(8.95)](/filings/0000950170-23-009046.md) | [(3.65)](/filings/0000950170-24-034868.md) | [(1.85)](/filings/0000950170-25-040771.md) | [(1.32)](/filings/0001193125-26-118532.md) | [(1.28)](/filings/0001193125-26-118532.md) |
| Free cash flow | $m | [(35.9)](/filings/0000950170-23-009046.md) | [(95.7)](/filings/0000950170-24-034868.md) | [(77.4)](/filings/0000950170-25-040771.md) | [(57.9)](/filings/0001193125-26-118532.md) | [(63.5)](/filings/0001193125-26-118532.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pyxs/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [GordonMD Global Investments LP](/funds/2039349.md) | 2026-06-30 | $30.2m | 10,024,909 |  | Added +5,903,039 |
| [Pfizer Inc](/funds/78003.md) | 2026-06-30 | $19.5m | 7,032,770 |  | Unchanged |
| [Laurion Capital Management LP](/funds/1390202.md) | 2026-06-30 | $14.8m | 4,900,888 |  | Reduced −96,445 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.2m | 2,075,997 |  | Added +42,487 |
| [Atle Fund Management AB](/funds/1381843.md) | 2026-06-30 | $2.9m | 966,459 |  | Added +769,423 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.6m | 867,934 |  | Added +79,095 |
| [Palo Alto Investors LP](/funds/1306923.md) | 2026-06-30 | $2.6m | 864,277 |  | Reduced −146,233 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $2.5m | 830,544 |  | Added +476,127 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.3m | 772,232 |  | Reduced −116,448 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.8m | 591,849 |  | Reduced −6,272 |

## Recent filings

[All 343 filings](/companies/pyxs/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-21 | 20:27 ET | [DEF 14A](/filings/0001193125-26-427882.md) | Proxy statement, period 2026-10-21 | 0001193125-26-427882 |
| 2026-10-01 | 21:24 ET | [8-K](/filings/0001437749-26-031767.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-031767 |
| 2026-09-09 | 11:34 ET | [8-K](/filings/0001193125-26-385901.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-385901 |
| 2026-09-08 | 11:39 ET | [8-K](/filings/0001193125-26-384386.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-384386 |
| 2026-08-13 | 11:44 ET | [10-Q](/filings/0001193125-26-347913.md) | Quarterly report, period 2026-06-30 | 0001193125-26-347913 |
| 2026-08-13 | 11:42 ET | [8-K](/filings/0001193125-26-347911.md) | 2.02 Results of operations | 0001193125-26-347911 |
| 2026-07-02 | 20:20 ET | [8-K](/filings/0001193125-26-294613.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure | 0001193125-26-294613 |
| 2026-06-15 | 20:22 ET | [8-K](/filings/0001193125-26-271137.md) | 5.07 Shareholder vote results | 0001193125-26-271137 |
| 2026-05-14 | 11:56 ET | [10-Q](/filings/0001193125-26-222843.md) | Quarterly report, period 2026-03-31 | 0001193125-26-222843 |
| 2026-05-14 | 11:36 ET | [8-K](/filings/0001193125-26-222818.md) | 2.02 Results of operations | 0001193125-26-222818 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-118532.md), filed Mar 23, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1782223
- Tickers: PYXS
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.